Inotrope and vasopressor use in cardiogenic shock: what, when and why?

Area of Science:

• Cardiology
• Critical Care Medicine
• Pharmacology

Background:

• Cardiogenic shock (CS) management remains challenging with high mortality rates.
• Vasopressors and inotropes are standard supportive treatments for CS, despite limited evidence.
• Current guidelines recommend these agents, but their safety and efficacy in CS are not well-established.

Purpose of the Study:

• To review the current evidence on vasopressor and inotrope use in cardiogenic shock.
• To highlight recent trial findings and ongoing research in CS pharmacotherapy.
• To provide guidance on inotrope selection in the absence of definitive evidence.

Main Methods:

• Literature review of current studies and clinical trials in cardiogenic shock.
• Analysis of findings from OptimaCC and CAPITAL DOREMI trials.
• Discussion of upcoming placebo-controlled trials (CAPITAL DOREMI2, LevoHeartShock).

Main Results:

• Norepinephrine is supported as a first-line vasopressor in CS (OptimaCC trial).
• Milrinone showed no superiority over dobutamine in reducing morbidity/mortality in CS (CAPITAL DOREMI trial).
• No specific vasopressor or inotrope has demonstrated significant mortality benefit in CS patients.

Conclusions:

• Evidence for significant mortality benefit with specific vasopressors or inotropes in CS is lacking.
• Upcoming trials will provide crucial data on the necessity of inotropes in CS.
• Inotrope selection should be individualized, considering physician experience, availability, cost, and patient response.